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Abstract
Changes in gene expression programs play a central role in cancer. Chromosomal aberrations such as deletions,
duplications and translocations of DNA segments can lead to highly significant positive correlations of gene expression
levels of neighboring genes. This should be utilized to improve the analysis of tumor expression profiles. Here, we develop a
novel model class of autoregressive higher-order Hidden Markov Models (HMMs) that carefully exploit local data-dependent
chromosomal dependencies to improve the identification of differentially expressed genes in tumor. Autoregressive higher-
order HMMs overcome generally existing limitations of standard first-order HMMs in the modeling of dependencies
between genes in close chromosomal proximity by the simultaneous usage of higher-order state-transitions and
autoregressive emissions as novel model features. We apply autoregressive higher-order HMMs to the analysis of breast
cancer and glioma gene expression data and perform in-depth model evaluation studies. We find that autoregressive
higher-order HMMs clearly improve the identification of overexpressed genes with underlying gene copy number
duplications in breast cancer in comparison to mixture models, standard first- and higher-order HMMs, and other related
methods. The performance benefit is attributed to the simultaneous usage of higher-order state-transitions in combination
with autoregressive emissions. This benefit could not be reached by using each of these two features independently. We
also find that autoregressive higher-order HMMs are better able to identify differentially expressed genes in tumors
independent of the underlying gene copy number status in comparison to the majority of related methods. This is further
supported by the identification of well-known and of previously unreported hotspots of differential expression in
glioblastomas demonstrating the efficacy of autoregressive higher-order HMMs for the analysis of individual tumor
expression profiles. Moreover, we reveal interesting novel details of systematic alterations of gene expression levels in
known cancer signaling pathways distinguishing oligodendrogliomas, astrocytomas and glioblastomas. An implementation
is available under www.jstacs.de/index.php/ARHMM.
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Received April 17, 2014; Accepted May 22, 2014; Published June 23, 2014
Copyright:  2014 Seifert et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Data Availability: The authors confirm that all data underlying the findings are fully available without restriction. Pollack breast cancer data is available from
Pollack JR, et al. (2002), PNAS 99: 12963–12968. Rembrandt glioma data is available from the Repository for Molecular Brain Neoplasia Data (Rembrandt, release
1.5.9, https://caintegrator.nci.nih.gov/rembrandt/). Tayrac glioma data is available from GEO (GSE10878). Cancer signaling pathway data is available from
ConsensusPathDB (http://cpdb.molgen.mpg.de/). An implementation of ARHMMs and considered gene expression data sets are available from http://www.jstacs.
de/index.php/ARHMM.
Funding: This work was done in the frame of the GlioMath-Dresden project funded by the European Social Fund and the Free State of Saxony. We acknowledge
support by the German Research Foundation and the Open Access Publication Funds of the TU Dresden.
Competing Interests: The authors have declared that no competing interests exist.
* Email: michael.seifert@zih.tu-dresden.de
Introduction
Copy number changes of genes are frequently found in different
types of cancer [1]. Mutations such as duplications of oncogenes
and deletions of tumor suppressor genes contribute together with
single nucleotide polymorphisms, epigenetic alterations and other
types of mutations to changes in gene expression programs
triggering the development of cancer [2]. Broad and focal
duplications and deletions of chromosomal regions are known to
directly influence expression levels of underlying genes. Genes with
increased copy numbers tend to show increased expression,
whereas genes with reduced copy numbers tend to show reduced
expression in tumors compared to healthy tissue (e.g. [3–6]). This
coupling of gene copy numbers and gene expression levels leads to
local chromosomal dependencies between gene expression levels
providing the opportunity to develop improved methods for the
analysis of individual tumor expression profiles.
Over the last years, several approaches have been developed for
the analysis of tumor expression profiles in the context of
chromosomal locations of genes. Methods like CGMA (compar-
ative genomic microarray analysis) [7], MACAT (MicroArray
Chromosome Analysis Tool) [8] or LAP (Locally Adaptive
statistical Procedure) [9] require replicated measurements of
tumor and normal reference samples for the identification of
differentially expressed genes. Such methods cannot be applied to
the analysis of individual tumor expression profiles in large
screenings for which repeated profiling of the same sample is
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typically not done to reduce costs and to increase the number of
screened tumors. Usually, log-fold change thresholds are used to
determine differentially expressed genes in individual tumor
expression profiles measured in such screenings. Alternatively,
closely related methods for the analysis of comparative genomic
hybridization data (e.g. reviewed and compared in [10] and [11])
can be applied to individual tumor expression profiles. For
example, ChARM (Chromosomal Aberration Region Miner) [12]
has also been demonstrated to identify differentially expressed
chromosomal regions in individual tumor expression profiles.
However, we have recently shown that both strategies only reach
suboptimal performances that can be improved substantially by
Hidden Markov Models (HMMs) utilizing prior knowledge on the
distribution of gene expression measurements and chromosomal
proximities of genes [13].
Generally, HMMs provide a sound mathematical grounding for
the analysis of biological sequences [14,15]. However, a current
limitation of almost all existing HMM -based approaches is their
limited potential to model local dependencies between measure-
ments due to two restrictive assumptions. First of all, the
commonly used standard first-order state-transition process only
enables the modeling of local dependencies between directly
adjacent hidden states. Secondly, it is commonly assumed that
measurements only depend on the underlying state and do not
directly influence each other. Nevertheless, HMMs with such
restrictive assumptions have frequently been found to reach good
results in a broad range of applications [14,16,17], but it has on
the other hand also been demonstrated that the integration of a
higher-order state-transition process can improve the model
performance substantially in speech recognition (e.g. [18]),
handwriting recognition (e.g. [19]), financial time-series analysis
(e.g. [20]), image segmentation (e.g. [21]), robotics (e.g. [22]) and
computational biology (e.g. [11,23,24]).
However, this only addresses the first limitation by overcoming
the restrictive first-order state-transition process. Independent
from that, extensions of the standard emission process have been
initially realized in speech recognition by the integration of
autoregressive emission distributions enabling the modeling of
state-specific direct local dependencies within a range of successive
measurements [25]. This concept has also been successfully
applied in other domains including the analysis of financial time
series [26], electrophysiological signals [27], evaluation of mete-
orological data [28], modeling of influenza and dengue fever
epidemics [29,30], speech synthesis [31] and for studying the
locomotive behavior of flies [32]. However, there have been no
general efforts to combine both concepts by realizing an HMM
with higher-order state-transitions and autoregressive emissions.
To overcome this, we develop a novel model class of
autoregressive higher-order HMMs enabling an improved mod-
eling of local dependencies between successive measurements.
Autoregressive higher-order HMMs simultaneously utilize higher-
order state-transitions in combination with autoregressive emis-
sions as novel model features. Globally, this model class has very
general modeling capabilities including mixture models, standard
first-order HMMs and higher-order HMMs as special cases. We
motivate the development of autoregressive higher-order HMMs
by considering the analysis of individual tumor expression profiles
in which local dependencies of gene expression levels are
frequently caused by deletions and duplications of underlying
chromosomal regions. The existence of such local chromosomal
dependencies between expression levels of genes in close
chromosomal proximity is clearly shown for three different types
of cancer in Figure 1. Additionally, based on initial findings on the
importance of integrating prior knowledge on the distribution of
differentially expressed genes into the training of HMMs [13], we
here also specifically design an efficient Bayesian Baum-Welch
training for autoregressive higher-order HMMs.
We apply our autoregressive higher-order HMMs to the
analysis of publicly available breast cancer and glioma gene
expression data. We first systematically evaluate the performance
of autoregressive HMMs to predict overexpressed genes in breast
cancer with known underlying increased gene copy numbers.
Then, we analyze to which extent these results are transferable to
other similar breast cancer expression profiles. We further
complement this by a sensitivity analysis evaluating the robustness
of autoregressive HMM predictions. Next, we perform an in-depth
comparison study to related existing methods on breast cancer
gene expression profiles, where we first investigate general
characteristics of predicted differentially expressed genes followed
by the identification of overexpressed genes with known increased
copy numbers. Finally, we consider different types of gliomas and
demonstrate that autoregressive HMMs are useful tools to reveal
systematic differences in expression levels of genes in known
cancer signaling pathways.
Materials and Methods
The materials part provides a brief overview of the considered
data sets. The methods part gives a detailed description of the
model class of autoregressive higher-order HMMs.
Figure 1. Local chromosomal dependencies of gene expression
levels in different types of cancer. Spatial correlations of expression
levels of genes in increasing chromosomal order up to ten were
quantified by an average autocorrelation function that considers each
chromosome-specific expression profile in each individual tumor
sample. The autocorrelation function quantifies the similarity of gene
expression levels of neighboring genes on a chromosome in a fixed
distance. Corresponding average autocorrelation functions are shown
for three types of cancer (i) different types of gliomas (red) [33], (ii)
breast cancer expression profiles (orange) [3] and (iii) glioblastoma
expression profiles (grey) [4]. Additionally, the green curve represents
the average autocorrelation function of normal brain reference gene
expression profiles taken from [33]. Due to chromosomal aberrations in
gliomas, expression levels of genes in close chromosomal proximity
tend to show greater similarity in gliomas (red) than in corresponding
normal brain tissues (green). Moreover, the black curve represents
mean values and standard deviations of the average autocorrelation
function for randomly permuted glioma gene expression profiles from
[33] across 100 repeats. The observation of significant local chromo-
somal dependencies in tumor expression profiles compared to
permuted expression profiles motivates the development of autore-
gressive higher-order HMMs for the analysis of tumor expression
profiles.
doi:10.1371/journal.pone.0100295.g001
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Materials
This section shortly introduces the considered breast cancer and
glioma data sets.
Breast Cancer Data. A breast cancer data set by Pollack et al.
[3] is used to compare different bioinformatics methods for their
potential to identify differentially expressed genes in breast cancer.
This data set contains gene expression levels and corresponding
gene copy numbers measured for 4 breast cancer cell lines and 37
tumors across 6,095 genes of the 23 human chromosomes. For
each chromosome in each cell line and each tumor, we
summarized the gene expression measurements in a chromo-
some-specific tumor expression profile ~o(k)~(o1(k), . . . ,oTk (k))
leading to k[f1, . . . ,943~(4z37)  23g different profiles. Each
profile represents the relative expression level of each gene
t[f1, . . . ,Tkg defined by the log2-ratio ot(k) of its expression level
in tumor divided by its corresponding expression level in the
healthy reference sample. All log-ratios in a tumor expression
profile are ordered from the p-arm to the q-arm of the underlying
chromosome utilizing the chromosomal locations of the corre-
sponding genes. A histogram of log-ratios of the breast cancer gene
expression data set is shown in Figure S1 in Text S1. Local spatial
dependencies between expression levels in the breast cancer gene
expression profiles are shown in Figure 1.
Glioma Data. We created a glioma gene expression data set
based on data from the Repository for Molecular Brain Neoplasia
Data (Rembrandt, current release 1.5.9) [33] containing tumor
samples of oligodendrogliomas (WHO grades II and III),
astrocytomas (WHO grades II and III) and glioblastomas
(glioblastoma multiforme: astrocytoma of WHO grade IV). We
performed stringent quality controls of the downloaded gene
expression arrays and removed all arrays with hybridization
artifacts. We further did a standard Affymetrix microarray
processing utilizing a customized design file from BrainArray
(HGU133Plus2 version 15.0.0) in combination with GCRMA
normalization [34]. The final data set contains tumor gene
expression profiles of 89 different gliomas (45 glioblastomas, 33
astrocytomas, and 11 oligodendrogliomas) for which gene
expression levels of 16,282 genes are quantified in terms of log-
ratios with respect to an average normal brain reference computed
based on data from Rembrandt. The individual tumor-specific
chromosomal expression profiles were structured in analogy to the
previously described breast cancer expression profiles. We use this
data set to perform an in-depth comparison of gene expression
changes affecting known cancer-relevant signaling pathways across
different types of gliomas. Local chromosomal dependencies
between gene expression levels in gliomas are shown in Figure 1.
Methods
This section develops the basics of the model class of
autoregressive higher-order HMMs in the context of the analysis
of tumor expression profiles. This includes a detailed model
description, a general characterization of the model class, the
integration of prior knowledge into the training of the model,
basics of the model training and the model initialization.
Autoregressive Higher-Order Hidden Markov
Models. We develop a three-state HMM with state-specific
autoregressive Gaussian emission densities for the identification of
differentially expressed genes in tumors. The set of hidden states of
the HMM is denoted by S : = {‘ = ’,‘2’,‘+’}. Considering the
usually observed distribution of log-ratios (e.g. Figure S1 in Text
S1), genes with unchanged expression levels between tumor and
normal tissue (log-ratios close to zero) are modeled by state ‘~’.
Underexpressed genes in tumor (log-ratios much less than zero)
are modeled by state ‘{’, and overexpressed genes in tumor
(log-ratios much greater than zero) are modeled by state ‘z’.
These states form the basis of the fully connected three-state
architecture of the HMM illustrated in Figure S2 in Text S1.
We utilize a homogeneous higher-order Markov model (e.g.
[35]) to model the state-transition process of the autoregressive
HMM. This has recently been shown to improve the analyses of
comparative genomics and DNA methylation data by a better
modeling of spatial dependencies between closely adjacent
chromosomal regions [11,24]. The state-transition process of an
HMM of order L§1 is specified by two components (i) an initial
Figure 2. Selected state space representations of models
included in the novel model class of autoregressive higher-
order HMMs. State space representations of selected models included
in the class of autoregressive higher-order HMMs. Hidden states are
denoted by Qt and emissions are denoted by Ot for t[f1, . . . ,Tg.
Arrows between nodes define modeled statistical dependencies. a)
Standard mixture model (AR(0)-HMM(0)). b) Mixture model with
second-order autoregressive emissions (AR(2)-HMM(0)). c) Standard
HMM with first-order state-transitions (AR(0)-HMM(1)). d) Standard
higher-order HMM with second-order state-transitions (AR(0)-HMM(2)).
e) Autoregressive higher-order HMM with second-order state-transi-
tions and second-order autoregressive emissions (AR(2)-HMM(2)).
doi:10.1371/journal.pone.0100295.g002
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state distribution~p : ~(pi)i[S with initial state probability pi[(0,1)
fulfilling the constraint
P
i[S pi~1 and (ii) a set of stochastic
transition matrices A : ~fA1, . . . ,ALg. Each transition matrix
Al : ~(aij)i[Sl ,j[S[A with 1ƒlƒL defines the transition proba-
bility aij[(0,1) for each transition from the current state il of a
state-context i~(i1, . . . ,il)[Sl to a next state j[S. This means that
for lw1 transitions from il are depending on its l{1 predecessors
i1, . . . ,il{1. Each transition matrix Al[A also fulfills the constraintP
j[S aij~1 for each i[S
l . More formally, the state-transition
process is used to model a hidden state sequence
~q(k) : ~(q1(k), . . . ,qTk (k)) that underlies a specific tumor expres-
sion profile ~o(k). The individual state of a gene t in a profile k is
denoted by qt(k)[S. To model the state sequence ~q(k), each
transition matrix Al with 1ƒlvL is used for the corresponding
transition from the current state ql(k) to the next state qlz1(k)
under consideration of the l{1 predecessor states
q1(k), . . . ,ql{1(k). Finally, the transition matrix AL[A is used
for each transition from qt(k) to qtz1(k) for all genes t§L in
dependency of the complete memory on L{1 predecessor states
qt{Lz1(k), . . . ,qt{1(k).
In addition to the higher-order state-transition process, we also
propose to model additional dependencies between emissions on
the level of the observed tumor expression profile utilizing higher-
order autoregressive Gaussian emission distributions. Similar to an
initial work in speech recognition by Ephraim et al. [25], we adapt
the concept of using an autoregressive emission process to the
analysis of tumor expression profiles. For each hidden state i[S,
we assume that the expression level ot(k) of a gene t in a profile k
is modeled by a state-specific autoregressive Gaussian emission
distribution of order M§0 defined by
bi(ot(k)) : ~
1ffiffiffiffiffi
2p
p
si
exp {
(ot(k){m
t
i (k))
2
2s2i
 !
with respect to the state-specific standard deviation si[R
z and the
state-specific autoregressive mean
mti(k) : ~miz
XM
m~1
cim:ot{m(k):dt,m ð1Þ
for the expression level of gene t in profile k. Here, mi[R defines
the basic state-specific mean and the coefficients (ci1, . . . ,ciM )[R
M
are used to model the impact of predecessor expression levels on
the gene-specific mean. Additionally, at the start of an emission
sequence, where the complete memory on M predecessor
emissions does not exist, we have to truncate the modeling of
dependencies by defining the function dt,m to be zero in cases
where t{mv1 and otherwise one. The emission parameters are
summarized in B : ~(mi,ci1, . . . ,ciM ,si)i[S . Additionally, all pa-
rameters of the autoregressive higher-order HMM are denoted by
l : ~(~p,A,B).
The identification of differentially expressed genes is done by
determining the probability with which each gene t in a tumor
expression profile~o(k) is assigned to a state i[S of the HMM. This
state-posterior probability ckt (i) : ~P½qt~i D~o(k),l  is computed
using extended Forward-Backward algorithms adapted to higher-
order HMMs [15]. The obtained state-posterior probabilities
enable (i) the ranking of individual genes according to their
potential of being differentially expressed and (ii) the determina-
tion of the most likely underlying state of each gene based on state-
posterior decoding (e.g. [15,36]). The autoregressive higher-order
HMM has been implemented using Jstacs [37].
Existing Models Covered by Autoregressive Higher-Order
Hidden Markov Models. We introduce the notation AR(M)-
HMM(L) to specify an HMM with an autoregressive emission
process of order M and a state-transition process of order L. This
model is part of the very general model class of autoregressive
higher-order HMMs. This model class contains several special
cases that have previously been studied in different domains also
including applications in computational biology. Some selected
underlying state space representations of specific models are shown
in Figure 2 for increasing model complexities enabling a better
modeling of dependencies between closely adjacent genes in a
tumor expression profile.
Figure 2a represents the mixture model AR(0)-HMM(0) (e.g.
[38]) that does not model any dependencies between genes. A
second-order autoregressive mixture model AR(2)-HMM(0) (e.g.
[39]) is exemplarily shown in Figure 2b. This model only realizes
dependencies between successive genes on the level of the
measured gene expression levels. The standard first-order HMM
AR(0)-HMM(1), which is very popular in applied sciences (e.g.
[15–17,36]), is shown in Figure 2c. This model integrates
dependencies between directly adjacent genes on a chromosome
on the level of the hidden state-transitions of adjacent genes. A
second-order HMM AR(0)-HMM(2) is exemplarily shown in
Figure 2d. Such higher-order HMMs are still rarely used in
practical applications, but they are known to be powerful
extensions of first-order HMMs (e.g. [11,18,19,24,40]). Finally, a
second-order HMM with second-order autoregressive emissions
denoted by AR(2)-HMM(2) is shown in Figure 2e.
Generally, autoregressive higher-order HMMs implement a
combination of higher-order state-transitions and autoregressive
emissions to improve the modeling of local chromosomal
dependencies between genes. The improved modeling of spatial
dependencies is reached at the price of an increased number of
model parameters and an increased computational complexity.
For an HMM with N states, an autoregressive emission process of
order M and a state-transition process of order L, the processing
of a tumor expression profile of length T generally requires
O(TNLz1M) operations. The factor NLz1 accounts for the state-
transitions and the factor M accounts for the emissions that have
to be processed for each of the T genes. Thus, in dependency of
available training data, only small model orders should be
considered in practical applications to avoid long training times
and overfitting. For the analysis of microarray data, models with a
state-transition process of order two up to four have shown the best
performance in previous studies with higher-order HMMs [11,24].
Integration of Prior Knowledge. The integration of prior
knowledge into the training of HMMs has been shown to be a key
feature for improving the identification of differentially expressed
genes in tumors [13]. Thus, to achieve a problem-specific
characterization of the autoregressive higher-order HMM, we
define a prior distribution
P½l DH  : ~D1(~p DH1 ):D2(A DH2 ):D3(B DH3 ) ð2Þ
over the space of the model parameters l : ~(~p,A,B) for given
hyper-parameters H : ~(H1,H2,H3). This prior distribution is
specified by a product of three independent prior distributions
enabling the integration of prior knowledge into the initial state
distribution, the set of transition matrices and the emission
parameters of the HMM. Following the usual choices of prior
distributions for HMMs (e.g. [11,13,14,24]), the prior D1(~p D H1 )
for the initial state distribution is defined by a Dirichlet distribution
ARHMM-Based Analysis of Tumor Expression Profiles
PLOS ONE | www.plosone.org 4 June 2014 | Volume 9 | Issue 6 | e100295
and the prior D2(A D H2 ) for the set of transition matrices is
specified by products of Dirichlet distributions. Both priors
represent conjugate priors enabling the analytical estimation of
model parameters during the training. Details of both prior
distributions are given in Appendix A in Text S1.
In the following, we summarize important characteristics of the
emission prior D3(B D H3 ) to enable the integration of prior
knowledge into the training of the state-specific autoregressive
Gaussian emission densities. To avoid that each gene t in a tumor
expression profile k has its specific emission prior, we define the
prior distribution for the state-specific autoregressive mean mti(k)
specified in Eqn. (1) using the following strategy. We only explicitly
model prior knowledge for each basic state-specific mean mi and
assume constant priors for the corresponding coefficients
(ci1, . . . ,ciM ). This leads to a reduction of the prior for m
t
i (k) to
a prior that is only depending on the corresponding mi. Based on
that, the emission prior for an HMM with autoregressive Gaussian
emissions can be defined by using a product of independent
Gaussian-Inverted-Gamma distributions as used for non-autore-
gressive HMMs in [13]. Details of this emission prior in the
context of autoregressive higher-order HMMs are provided in
Appendix A in Text S1.
Bayesian Baum-Welch Training. The training of the
autoregressive higher-order HMM is done by a Bayesian Baum-
Welch algorithm enabling the integration of prior knowledge into
the iterative parameter estimation process. This algorithm belongs
to the class of Expectation-Maximization (EM) algorithms [41]
and extends the typically used Baum-Welch training [36,42] that
does not utilize prior knowledge. In our context, the term
‘Bayesian’ specifies a Maximum-A-Posterior (MAP) estimate
integrated into an EM algorithm. A specific version of a Bayesian
Baum-Welch algorithm has been developed in [13] for first-order
HMMs. This algorithm has been adapted to higher-order HMMs
in [24]. Here, we further extend this algorithm to the requirements
of autoregressive higher-order HMMs. The Bayesian Baum-
Welch algorithm locally maximizes the log-posterior by a two-step
procedure based on initially chosen model parameters. This is
realized by iteratively determining new parameters
l(hz1)~ argmax
l
Q(l Dl(h) )z log (P½l DH )ð Þ
maximizing the log-posterior of the model l with respect to the
current parameters of the model l(h) (h~1 initial model). The log-
posterior is specified by a combination of Baum’s auxiliary
function Q(l D l(h) ) (Appendix B in Text S1; [13,24,36]) and the
logarithm of the prior distribution P½l D H  in Eqn. (2). This
combination enables the iterative estimation of new model
parameters under consideration of prior knowledge. The process
of estimating new parameters l(hz1) is iterated until the log-
posterior increases less than a predefined threshold in comparison
to the value obtained for the previous parameters l(h). We stop
the training if the increase of the log-posterior is less than 10{3 for
two successive iterations.
Since we propose autoregressive Gaussian emissions as a novel
model feature, we briefly summarize important steps of the
estimation of the corresponding autoregressive means. The
maximization step of the emission parameter estimation part of
the log-posterior leads to a state-specific system of linear equations
that enables to update the basic mean and the corresponding
coefficients for each autoregressive mean. Standard solvers for
systems of linear equations can be used to compute the solution of
the given system. We utilize the publicly available Jama package
[43] to compute each state-specific autoregressive mean.
Specific details of the estimation of initial state, transition and
emission parameters of the autoregressive higher-order HMM and
a computational scheme of the training algorithm are given in
Appendix B in Text S1.
Model Initialization. For the identification of differentially
expressed genes in tumors, an initial autoregressive HMM must be
specified to enable a good adaptation of the model to the data
during the training. We transfer initial model and prior settings
described in [13] to autoregressive HMMs. The initial state
probabilities are set to p{~pz : ~0:1 and p~ : ~0:8 assuming
that the proportion of differentially expressed genes is much less
than the proportion of genes with unchanged expression behavior.
We further assume that the initial transition matrix A1 : ~(aij)i,j[S
has a stationary distribution identical to the initial state
distribution ~p. This is done by defining state-specific diagonal
elements aii : ~1{s=pi and non-diagonal elements aij : ~s=(2pi)
with respect to a scaling factor s~0:05 for controlling the state
durations. Additionally, in analogy to [24], the transition
probabilities of each transition matrix Al : ~(aij)i[Sl ,j[S with
1vlƒL are initially set to aij : ~ail j defining that the transition
probability from each state-context i : ~(i1, . . . ,il) to a state j is
identical to the value of the corresponding transition probability
ail j in A1. The initial state-specific autoregressive Gaussian
emission densities are characterized by basic means m{ : ~{2,
m~ : ~0 and mz : ~2 and corresponding standard deviations
s{ : ~0:3, s~ : ~0:5 and sz : ~0:3. Additionally, we set each
corresponding initial autoregressive coefficient cim : ~0. We also
utilize these settings to specify appropriate prior knowledge for the
training of the emission parameters of each state. Details of this are
given in Appendix A in Text S1.
This basic initialization strategy has led to robust results in [13].
We here further performed an in-depth sensitivity analysis by
systematically varying initial model and prior parameter settings to
quantify the impact on the predictions made by autoregressive
HMMs. We find that changes of parameter settings do not
substantially influence the predictions (see results section for more
details). Yet, users are still able to change these settings to enable
modeling of specific characteristics of other data sets. However,
this was not necessary for the analysis of the three different tumor
data sets that we have analyzed here.
With the goal of performing exhaustive comparisons of different
autoregressive HMMs, we trained each HMM with an auto-
regressive emission process of order M[f0, . . . ,5g in combination
with a state-transition process of order L[f0, . . . ,5g on the breast
cancer expression profiles using the developed Bayesian Baum-
Welch algorithm. This was done using the proposed initial basic
settings. These settings were also used for the analysis of the glioma
data sets.
Results/Discussion
In this section, we first systematically compare different
autoregressive HMMs for their performance to identify overex-
pressed genes with underlying increased copy numbers in breast
cancer. Next, we analyze to which extent the obtained results can
be transferred to other similar breast cancer gene expression
profiles. This is complemented by performing a sensitivity analysis
to study the robustness of predictions obtained by autoregressive
HMMs. After that, we compare the performance of autoregressive
HMMs to related existing methods. Here, we first investigate the
different methods for general characteristics of their predictions of
differentially expressed genes. We further compare the different
methods based on their identification of overexpressed genes with
underlying increased copy numbers in breast cancer. Finally, we
ARHMM-Based Analysis of Tumor Expression Profiles
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transfer autoregressive higher-order HMMs to different types of
gliomas and perform an in-depth systematic analysis of differen-
tially expressed genes with respect to known cancer signaling
pathways.
Identification of Overexpressed Genes with Increased
Gene Copy Numbers by Autoregressive Higher-Order
Hidden Markov Models of Different Model Complexities
We utilize breast cancer gene expression and corresponding
gene copy number data by Pollack et al. [3] to compare
autoregressive HMMs with different combinations of emission
and transition orders for their ability to predicted overexpressed
genes with underlying increased copy numbers. This is generally
motivated by a frequently observed direct genome-wide coupling
between gene expression levels and gene copy numbers. Different
studies comparing tumor to healthy tissue have found that genes
with increased copy numbers tend to be overexpressed, while
genes affected by deletions tend to be underexpressed in tumors
(e.g. [3–6,44,45]). Since mutations in trans-acting factors (e.g.
transcription factors or protein kinases) also lead to alterations of
gene expression levels in tumor, there is of course not a direct one-
to-one relationship between the expression level and the copy
number of each gene. Still, genes affected by copy number
alterations can be used to initially characterize and evaluate the
identification of differentially expressed genes by different auto-
regressive HMMs.
Here, we do this in analogy to Seifert et al. [13] utilizing the
strong coupling between overexpression and increased copy
numbers of genes present in the breast cancer data set [3]. Based
Figure 3. Identification of overexpressed genes with increased copy numbers in breast cancer by different autoregressive HMMs.
Systematic comparison of the identification of overexpressed genes with at least three-fold increased copy numbers by autoregressive HMMs based
on breast cancer gene expression profiles from [3]. Each AR(M)-HMM(L) with an emission process of order M[f0, . . . ,5g (AR(M)) in combination with
a state-transition process of order L[f0, . . . ,5g (HMM-Order) is considered. The left column shows the performances reached by autoregressive
HMMs trained and applied to fifty percent of the breast cancer gene expression data. The right column shows the performances of these models
reached on the remaining unseen fifty percent of the data set. For each model, the identification of candidate genes of overexpression with at least
three-fold increased copy numbers is quantified by the true positive rate (TPR) reached at a fixed false positive rate of 5%. Six different scenarios are
shown. a) and b) represent performances of the different models with respect to our standard initial model parameter settings. c) and d) represent
average performances and corresponding standard deviations reached with respect to systematically changed initial model parameters. e) and f)
represent average performances and corresponding standard deviations reached with respect to systematically modified prior hyperparameter
settings. The predictions of autoregressive HMMs are generally very robust. Models utilizing a combination of higher-order state-transitions and
autoregressive emissions (e.g. AR(4)-HMM(2) and AR(2)-HMM(2)) are clearly outperforming the mixture model (AR(0)-HMM(0)), the standard first-order
HMM (AR(0)-HMM(1)), and standard higher-order HMMs (AR(0)-HMM(L)).
doi:10.1371/journal.pone.0100295.g003
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on that, we determined potential candidate genes of overexpres-
sion for each individual tumor sample using its corresponding
individual gene copy number profile. For each individual tumor
expression profile, each gene with an underlying increased gene
copy number in tumor compared to normal was considered as a
potential candidate for overexpression. We used three different
copy number cutoffs (two-, three-, four-fold) for the selection of
candidate genes of overexpression to evaluate the robustness of the
model comparisons. The majority of these candidate genes tend to
be overexpressed in breast cancer (Figure S3 in Text S1).
To analyze the performance of the identification of overex-
pressed genes with underlying increased copy numbers by different
autoregressive HMMs, we used fifty percent of the breast cancer
gene expression data set. We trained each initial AR(M)-HMM(L)
with an autoregressive emission process of order M[f0, . . . ,5g in
combination with a state-transition process of order L[f0, . . . ,5g
using the developed Bayesian Baum-Welch algorithm. We then
compared the different models based on their performance to
identify candidate genes of overexpression with at least three-fold
increased copy numbers. To measure the performance of each
individual model, we first ranked all genes according to their
potential of being overexpressed utilizing the corresponding state-
posteriors of state ‘z’. Based on that, we computed the true
positive rate (TPR) of predicted potential candidate genes of
overexpression reached at a typically considered fixed small false
positive rate (FPR) of 5%. The reached performances are shown in
Figure 3a. Similar results were reached considering the identifi-
cation of candidate genes of overexpression with at least two- or
four-fold increased copy numbers (Figure S4a in Text S1).
Generally, comparing well-known standard models included in
the class of autoregressive higher-order HMMs, the mixture model
(AR(0)-HMM(0)), which does not model dependencies between
expression levels of genes, and the autoregressive mixture model
(AR(M )-HMM(0) with M§1), which directly models dependen-
cies between expression levels of successive genes on chromo-
somes, are outperformed by non-autoregressive HMMs (AR(0)-
HMM(L) with L§1: black curves in Figure 3a), which integrate
dependencies between genes using state-transitions. This extends
previous findings where standard mixture models have been
outperformed by first-order and higher-order HMMs [11,13,24].
Moreover, these performances can be further improved by
autoregressive higher-order HMMs (AR(M )-HMM(L) with
M§1 and L§1; non-black curves in Figure 3a). Especially,
autoregressive HMMs with an emission process of order two up to
four in combination with a state-transition process of order two up
to three reached the best performances.
In summary, autoregressive higher-order HMMs have the
potential to improve the identification of candidate genes of
overexpression with underlying increased gene copy numbers.
However, this is not limited to the identification of overexpressed
genes with underlying increased copy numbers in general. We
have already previously shown on the same data set that HMMs
with identical initial model parameters as considered here are
valuable for the identification of hotspot genes of differential
expression in breast cancer [13]. Thus, since the autoregressive
HMMs considered here and the previously considered HMMs
were very similar after training, this characteristic is also
transferred to autoregressive HMMs.
Transfer of Autoregressive Higher-Order Hidden Markov
Models to Similar Breast Cancer Gene Expression Profiles
Next, we utilized the remaining fifty percent of the previously
considered breast cancer gene expression data set to test the
performance of the previously trained autoregressive HMMs on
other similar but previously unseen gene expression profiles.
Generally, we note that such a transfer is only convenient if both
data sets have similar measurement characteristics (e.g. distribu-
tion of log-ratios, relatively similar expression profiles). This is also
reflected in closely related array comparative genomic hybridiza-
tion (aCGH) data analysis pipelines, where models are initially
adapted and later used for the analysis of a single individual data
set, but where transfers of trained models to other data sets are
typically not done. However, a successful transfer of trained
HMMs from one data set to a new data set can especially save
time for the analysis of large data sets by avoiding time-consuming
training steps. Thus, we transferred all previously trained
autoregressive HMMs to other similar breast cancer gene
expression profiles to evaluate the reached model performances
after this transfer in analogy to our previous study.
The results are summarized in Figure 3b. Similar results were
obtained for the identification of candidate genes of overexpression
with at least two- or four-fold increased copy numbers (Figure S4b
in Text S1). We find that the transfer of trained autoregressive
HMMs to other similar breast cancer data leads to prediction
characteristics (Figure 3b) that are comparable in shape with the
predictions reached on the data initially used to train the models
(Figure 3a). However, as expected, the transfer of models from the
initially used training data to other independent tumor expression
profiles leads to a reduction of the prediction performance (in
average a reduction of 3.8 in TPR for HMMs excluding mixture
models that gained 1.9 in TPR at a fixed FPR of 5%). Still,
autoregressive higher-order HMMs outperform standard non-
autoregressive first- and higher-order HMMs. Again, second-order
HMMs with autoregressive emissions of order two or four (AR(2)-
HMM(2), AR(4)-HMM(2)) are among the best models. Apart from
that, the relatively unstable predictions of autoregressive HMMs
with a fifth-order emission process (AR(5)-HMM(L) with L§1) on
the training data are also transferred to the test data (grey curves in
Figure 3). Since both data sets have similar measurement
distributions, this tends to reflect an overadaptation due to the
large number of free emission parameters.
Thus, this study indicates that a careful transfer of previously
trained autoregressive HMMs to other similar tumor expression
profiles can be realized, but one should keep in mind that a faster
analysis of large data sets may result in reduced accuracy of
predictions.
Analysis of the Robustness of Predictions Made by
Autoregressive Higher-Order Hidden Markov Models
We additionally performed a sensitivity analysis by systemati-
cally varying initial model parameters and prior parameter settings
to analyze the robustness of the predictions made by autoregres-
sive HMMs. Since this is generally very time-consuming, we
focused on those parameters that are expected to have the greatest
influence on the prediction of differentially expressed genes. We
first tested twelve different model initializations and trained
corresponding autoregressive HMMs on fifty percent of the breast
cancer gene expression data set using identical prior hyperpara-
meter settings. Specific details are given in Table S1 in Text S1.
We considered each AR(M )-HMM(L) with an autoregressive
emission process of order M[f0, . . . ,5g in combination with a
state-transition process of order L[f0, . . . ,5g under consideration
of clearly varying initial model parameters. In analogy to the two
previous model evaluation studies, we evaluated the prediction of
overexpressed genes with underlying increased gene copy numbers
by the different trained autoregressive HMMs on the initially
considered training data and on other similar breast cancer gene
expression profiles. We generally find that the corresponding
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predictions of the different autoregressive HMMs are very stable
(Figure 3c and d) and widely comparable to those reached by
autoregressive HMMs utilizing our generally considered initial
model parameterization specified in the methods section (Figure 3a
and b). Similar results were reached considering the identification
of overexpressed genes with at least two- or four-fold increased
copy numbers (Figure S5 in Text S1).
We next tested twelve different prior parameter settings and
trained the corresponding autoregressive HMMs utilizing our
generally considered fixed initial model parameterization de-
scribed in the methods section. Details of the tested prior
parameter settings are provided in Table S1 in Text S1. Again,
we find that the predictions of the corresponding autoregressive
HMMs are very stable (Figure 3e and f). The predictions reached
by autoregressive HMMs based on the twelve different prior
parameter settings vary slightly more than those reached for the
twelve different model initializations. Still, we clearly find that
autoregressive HMMs have the potential to improve the predic-
tions of overexpressed genes with underlying increased copy
numbers compared to mixture models (AR(0)-HMM(0)) and
standard first- or higher-order HMMs (AR(0)-HMM(L) with
L§1). This is also transferred to predictions of overexpressed
genes with at least two- or four-fold increased copy numbers
(Figure S6 in Text S1).
In summary, this study indicates that changes of the initial
model parameter settings and of the prior parameter settings do
not substantially affect the predictions of autoregressive HMMs.
Thus, the predictions of autoregressive HMMs are robust with
respect to reasonable changes of initial parameter settings.
Comparison of General Characteristics of the
Identification of Differentially Expressed Genes by
Autoregressive Higher-Order Hidden Markov Models to
Related Methods
To compare the identification of differentially expressed genes
by autoregressive HMMs to related methods, we analyzed the
breast cancer gene expression data set [3] using the AR(4)-
HMM(2) and nine other methods. We include ChARM [12],
which has been demonstrated to work on aCGH and tumor
expression profiles into this comparison. We also compare our
model to MixMod and DSHMM, which both were specifically
developed for the analysis of tumor expression profiles [13].
Additionally, we also include methods from the closely related field
of aCGH analysis (Wavelet [46], BioHMM [47], FHMM [48],
CBS [49], CGHseg [50], GLAD [51]) into this comparison. A
more detailed summary of considered methods is given in Table
S2 in Text S1.
We applied all methods with their proposed initial standard
settings to all breast cancer gene expression profiles. We note that
experts of specific methods might be able to further improve the
predictions by fine-tuning of specific model parameters. The
different methods implement specific algorithms to adapt their
initial parameters or test statistics to the data followed by the
prediction step. All methods except ChARM, DSHMM, AR(4)-
HMM(2) and MixMod were run on the ADaCGH web-server
[52]. The ADaCGH output assigns one of the three labels ‘{’,
‘~’, or ‘z’ to each gene in a tumor expression profile. This can be
directly interpreted as underexpressed, unchanged expressed, or
overexpressed in tumor compared to healthy tissue. For ChARM,
each non-significantly changed gene was labeled as unchanged
expressed and each significantly changed gene was labeled either
as underexpressed or overexpressed depending on the sign of the
corresponding log-ratio. For DSHMM, AR(4)-HMM(2) and
MixMod, we utilize the corresponding state-posterior decoding
to assign the most likely label to each gene. We further note that
we utilized the same initial basic settings as reported in the method
sections for DSHMM, AR(4)-HMM(2) and MixMod to enable an
unbiased direct comparison of these three methods.
To characterize the potential of the different methods to identify
differentially expressed genes, we first determined for each method
the proportions of predicted under- and overexpressed genes in
relation to the total number of measured genes. Additionally, we
computed the means and the standard deviations of measured log-
Table 1. Method-specific characteristics for the identification of differentially expressed genes in breast cancer.
Underexpressed Genes Overexpressed Genes
Method Reference Prop. Mean Sd Prop. Mean Sd Runtime
Wavelet [46] 18.58% 20.09 0.63 9.52% 0.13 0.84 3 min 36 s
BioHMM [47] 7.41% 20.30 0.88 9.96% 0.39 0.90 5 min 03 s
FHMM [48] 6.37% 20.37 0.75 5.42% 0.62 0.92 2 min 59 s
CBS [49] 2.66% 20.19 0.72 1.91% 0.47 0.98 3 min 02 s
CGHseg [50] 2.45% 20.11 0.64 0.97% 0.33 1.10 2 min 52 s
ChARM [12] 1.02% 20.30 0.66 1.84% 0.31 0.77 -
GLAD [51] 1.54% 21.95 1.00 1.77% 1.85 0.76 2 min 51 s
DSHMM [13] 1.48% 22.18 0.97 2.25% 1.90 0.70 1 min 26 s
AR(4)-HMM(2) see Methods 1.51% 22.23 0.88 2.19% 1.85 0.66 2 min 56 s
MixMod [13] 1.34% 22.39 0.81 1.84% 2.13 0.57 11 s
The proportion of genes predicted as under- or overexpressed in relation to the total number of measured genes and the corresponding means and standard deviations
of the underlying measured log-ratios are summarized for each method based on the the breast cancer gene expression data set from [3]. The different methods were
grouped into three categories according to their proportion of identified differentially expressed genes and the corresponding mean log-ratio columns. The rightmost
column specifies the runtimes of the different methods required to analyze the data set. All methods except ChARM, MixMod, DSHMM and AR(4)-HMM(2) were run on
the ADaCGH web-server [52] utilizing parallel computations (AMD Opteron 2.2 GHz CPUs with 6 GB RAM). The remaining methods were run on a standard laptop with
Intel CPU T9500 2.6 GHz and 2 GB RAM.
doi:10.1371/journal.pone.0100295.t001
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ratios for genes predicted as under- and overexpressed by each
method. Generally, the proportion of predictions quantifies the
prediction behavior of each method, and this measure in
combination with the mean and the standard deviation of the
log-ratios allows to analyze the ability to predict differentially
expressed genes. Finally, we also measured the runtime of each
method required for the analysis of the breast cancer data set. The
results are summarized in Table 1.
We generally observe that the methods can be grouped into
three classes. The first class represents Wavelet, BioHMM and
FHMM, which all predict a much larger proportion of under-
expressed and overexpressed genes than all other methods.
However, for these methods, the means and the standard
deviations of the corresponding log-ratios show that a large
proportion of predicted differentially expressed genes have log-
ratios that are close to zero. Additionally, genes predicted as
underexpressed can have log-ratios greater than zero. Vice versa,
genes predicted as overexpressed can have log-ratios less than
zero. This does not represent a solid identification of differentially
expressed genes, because underexpressed genes are expected to
have log-ratios much less than zero and overexpressed genes are
expected to have log-ratios much greater than zero. Thus, these
methods should not be transferred to the analysis of tumor gene
expression data. The second class consists of CBS, CGHseg and
ChARM that all predict much less underexpressed and overex-
pressed genes than the methods of the first class. However, still the
same problems as observed for methods from the first class occur.
The methods represented by the third class are GLAD, DSHMM,
AR(4)-HMM(2) and MixMod. These four methods also predict a
much smaller number of genes as underexpressed and overex-
pressed than methods of the first class. Additionally, the predicted
underexpressed and overexpressed genes reflect corresponding
characteristic log-ratios as expected for differentially expressed
genes. That is, genes predicted as underexpressed have log-ratios
clearly less than zero and genes predicted as overexpressed have
log-ratios clearly greater than zero. Thus, the autoregressive
higher-order HMM and the three other methods reach a solid
identification of differentially expressed genes in individual tumor
expression profiles. The runtimes of these methods were all less
than three minutes. Since the standard mixture model (MixMod)
does not model chromosomal dependencies between adjacent
genes, it was extremely fast requiring only 11 seconds. However,
the AR(4)-HMM(2) with a fourth-order emission process and a
second-order state-transition process had nearly the same runtime
as GLAD, which was run on the ADaCGH web-server utilizing
parallel computations. To further evaluate all different methods,
we subsequently study how the more complex modeling of local
chromosomal dependencies by autoregressive higher-order
HMMs influences the predictions of overexpressed genes with
known underlying increased copy numbers in comparison to the
other methods.
Comparison of the Identification of Overexpressed Genes
with Increased Copy Numbers by Autoregressive Higher-
Order Hidden Markov Models to Related Methods
We next exemplarily compare the identification of potential
candidate genes of overexpression with underlying increased gene
copy numbers by the AR(4)-HMM(2) to all nine previously
considered methods. Especially, the comparison to the DSHMM,
a first-order HMM that integrates spatial distances of adjacent
genes into the transition process, is of great interest, because this
model has previously been identified to reach the best perfor-
mance in a similar study [13]. We utilized the predictions from the
previous sections to rank the genes according to their decreasing
potential of being overexpressed. Due to the lack of method-
specific scores for performing rankings of genes for methods run
on the ADaCGH web-server and ChARM, we computed average
segmental log-ratios based on the corresponding discrete segmen-
tations returned for each individual tumor expression profile.
Based on that, we assigned the corresponding average segmental
log-ratio to each gene enabling us to rank the genes according to
their potential of being overexpressed. For AR(4)-HMM(2),
DSHMM, and MixMod, we utilized the state-posteriors of state
‘z’ modeling overexpressed genes to rank the predictions. Based
on that, we evaluated the prediction of candidate genes of
overexpression with at least two-, three- or four-fold increased
copy numbers in the breast cancer data set [3] at different levels of
false positives. The corresponding receiver operating characteristic
(ROC) curves for predicted overexpressed genes with at least
three-fold increased copy numbers are shown in Figure 4. Very
similar ROC curves were obtained for the prediction of
overexpressed genes with at least two- or four-fold increased copy
numbers (Figure S7 in Text S1). An additional comprehensive
summary for true positive rates reached at small fixed false positive
rates and globally reached areas under the ROC curves are given
in Table S3 in Text S1. Generally, we find that the AR(4)-
HMM(2) outperforms all methods including the DSHMM
previously identified as the best performer [13]. This performance
benefit can be attributed to the more complex modeling of spatial
dependencies between genes by utilizing a higher-order state-
transition process in combination with an autoregressive emission
process. That this more complex modeling leads to a gain in
performance is clearly shown by the comparison of the AR(4)-
HMM(2) to the mixture model (MixMod), which does not model
dependencies between genes (see Figure 2 for underlying state
space representation), and by the comparison to the DSHMM,
Figure 4. Comparison of an autoregressive higher-order HMM
to related existing methods. Comparison of the AR(4)-HMM(2) and
related methods with respect to the identification of overexpressed
genes with at least three-fold increased copy numbers based on breast
cancer data from [3]. The performance of each method is quantified by
a receiver operating characteristic (ROC) curve displaying the true
positive rate (TPR) reached at different levels of false positive rates
(FPR). The AR(4)-HMM(2) with a fourth-order autoregressive emission
process and a second-order state-transition process reaches the best
performance (red).
doi:10.1371/journal.pone.0100295.g004
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which specifically models dependencies between directly adjacent
genes on a chromosome.
Together with the previous finding that autoregressive HMMs
can identify differentially expressed genes independent of under-
lying gene copy numbers (Table 1), this analysis further supports
that autoregressive HMMs are useful for the identification of
differentially expressed genes in tumors.
Application of Autoregressive Higher-Order Hidden
Markov Models to Glioma Data
Finally, we apply our autoregressive higher-order HMMs to
different case studies utilizing publicly available glioma gene
expression data sets. Here, we exemplarily report the most striking
findings concerning the systematic analysis of gene expression
changes in known cancer signaling pathways. The other case
studies focusing on the identification of hotspots of differential
expression in glioblastomas based on a data set by de Tayrac [4] and
corresponding expression patterns of hotspot genes in different
types of gliomas from the Rembrandt repository are summarized
in Appendix C in Text S1. Briefly, we were able to identify seven
novel previously unreported hotspots of differential expression in
glioblastomas that we discuss together with other interesting
hotspot genes identified under less stringent hotspot criteria. In the
following, we focus on the in-depth analysis of the predictions
obtained for different types of gliomas with respect to known
cancer signaling pathways.
Systematic Analysis of Gene Expression Changes in
Different Types of Gliomas With Respect to Known
Cancer Signaling Pathways. Here, we investigate the poten-
tial of autoregressive higher-order HMMs to identify alterations of
expression levels of genes in known cancer signaling pathways for
different types of gliomas (oligodendrogliomas, astrocytomas,
glioblastomas). The classification of gliomas according to these
subtypes has important implications for the prognosis and the
treatment of glioma patients [53]. However, differences in gene
expression levels of known cancer signaling pathways are still
poorly understood and not well characterized. We therefore
adapted the AR(4)-HMM(2) based on the initial standard settings
described in the methods section to the average expression profile
of gliomas in the Rembrandt repository and used the obtained
model to predict the expression behavior in each individual glioma
sample. This prediction was done by computing the state-posterior
probabilities of the states ‘{’ and ‘z’ under the AR(4)-HMM(2)
for each individual gene in each individual tumor to obtain a
measure that enables to distinguish how likely it is that a specific
gene is underexpressed or overexpressed in tumor compared to the
normal brain reference. We now summed these gene-specific
probability scores of state ‘{’ and ‘z’ across all oligodendrogli-
omas, astrocytomas and glioblastomas separately to obtain ranking
lists of top candidate genes of under- and overexpression for the
three different types of gliomas. We then analyzed the overlap of
the resulting top genes of under- and overexpression and known
cancer signaling pathways based on the KEGG pathways in
cancer overview (path:hsa05200) for which we compiled corre-
sponding pathway genes based on ConsensusPathDB [54]. We
further extended the initial KEGG cancer pathway view by
systematically adding other known cancer-relevant pathways for
DNA repair, Telomere maintenance, DNA replication and
Hedgehog signaling (see Table S4 in Text S1 for an overview
with functional annotations). Based on this, we systematically
considered increasing numbers of top ranking genes of under- and
overexpression and determined the corresponding numbers of
genes that overlap with the individual cancer signaling pathways.
A representative global overview of how strongly oligodendro-
gliomas, astrocytomas and glioblastomas are affected by under-
and overexpression in specific cancer signaling pathways with
respect to random expectations is shown for the top 300 genes in
Figure S8 in Text S1. Globally looking at all genes in pathways
together, we find a significant enrichment of top-ranking
overexpressed genes across all known cancer signaling pathways
for each type of glioma. These enrichments were at least twice as
much as randomly expected (90 genes in oligodendrogliomas, 91
genes in astrocytomas and 102 genes in glioblastomas compared to
45 expected by chance at the level of the top 300). We do not
observe such global trends across all known cancer signaling
pathways for the top-ranking underexpressed genes. Each type of
glioma showed nearly the same number of underexpressed genes
than randomly expected (48 genes in oligodendrogliomas, 50
genes in astrocytomas and 47 genes in glioblastomas compared to
45 expected by chance at the level of the top 300).
In more detail, considering underexpressed genes, we observe
that the same cancer signaling pathways are always affected by
nearly the same number of genes independent of the type of
glioma (Figure S8a in Text S1). In comparison to random
expectations, the pathways that are most strongly affected by
underexpression are MAPK, ErbB, TGF-Beta and VEGF
signaling. These pathways play important roles in the regulation
of cell proliferation, differentiation, migration, survival, adhesion,
apoptosis and angiogenesis. It is also interesting to note that we do
not observe underexpressed genes in p53 signaling, Notch
signaling, and Hedgehog signaling, Cytokine-cytokine receptor
interaction, DNA replication, DNA repair, and Telomere
maintenance across the three different types of gliomas.
In contrast to this, these pathway-based characteristics are
largely different considering the top 300 overexpressed genes
(Figure S8b in Text S1). The most homogeneous behavior in terms
of number of overexpressed genes across the three different types
of gliomas is observed for the cell cycle, Wnt signaling and p53
signaling pathways. The Wnt pathway plays important roles in cell
polarization, proliferation, differentiation and migration, whereas
the p53 pathway has a central role in cellular signaling with major
functions in controlling apoptosis, cellular senescence and cell
cycle arrest. Dysregulation of both signaling pathways is
commonly found in various cancers [55,56]. Interestingly, in
addition to the homogeneous behavior of these three pathways, we
also observe significant differences between oligodendrogliomas,
astrocytomas and glioblastomas at the level of the top 300
overexpressed genes that we analyze in the following.
Considering increasing numbers of top-ranking overexpressed
genes, we observe robust systematic differences between oligoden-
drogliomas, astrocytomas and glioblastomas for PI3K-Akt signal-
ing, Focal adhesion, ECM-Receptor interaction, TGF-Beta
signaling, VEGF signaling, Notch signaling, Telomere mainte-
nance and DNA repair (Figure 5). Glioblastomas show clearly
more overexpressed genes in PI3K-Akt signaling, Focal adhesion
and ECM-Receptor interaction than astrocytomas, which show a
greater number of overexpressed genes in these pathways than
oligodendrogliomas. Since these pathways are known to be
involved in cell survival, proliferation, migration and metabolism,
a systematic increase in overexpressed genes may lead to increased
pathway activities contributing to the generally observed increased
malignancy of glioblastomas in comparison to astrocytomas and
oligodendrogliomas [53]. Interestingly, we observe an inverse
behavior for TGF-Beta signaling, Notch signaling, Telomere
maintenance, and DNA repair (Figure 5). For these pathways,
oligodendrogliomas show the greatest number of overexpressed
genes followed by astrocytomas, which tend to have a greater
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Figure 5. Most discriminative signaling pathways distinguishing different types of gliomas. Overview of known cancer signaling
pathways identified to show largely distinct patterns of overexpressed genes in oligodendrogliomas, astrocytomas and glioblastomas based on
predictions of the AR(4)-HMM(2). The overlap of the top-ranking overexpressed genes with the specific signaling pathways is quantified from top 100
to top 600. Grey curves show random expectations with respect to the number of genes in a specific pathway. Robust systematic differences
between the different types of gliomas are clearly visible.
doi:10.1371/journal.pone.0100295.g005
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number of overexpressed genes than glioblastomas. Since TGF-
Beta signaling is involved in apoptosis and cell cycle arrest and
since an increased expression of Telomere maintenance and DNA
repair pathways may contribute to more stable tumor genomes,
this increased number of overexpressed genes observed for
oligodendrogliomas may be associated with the generally better
prognosis of oligodendrogliomas in comparison to astrocytomas
and glioblastomas [53]. These observations further sharpen and
support initial findings that expression profiles of oligodendrogli-
omas are enriched in overexpressed genes involved in DNA repair
in a study comparing oligodendrogliomas, astrocytomas and
glioblastomas [57]. Additionally, also the revealed over-represen-
tation of the Notch pathway in oligodendrogliomas and astrocy-
tomas compared to glioblastomas is very interesting. Differences in
the activities of the Notch pathway have been observed between
astrocytomas and glioblastomas [58]. Moreover, the Notch
pathway has been reported to mediate opposite effects either
acting in an oncogenic or tumor-suppressive manner in depen-
dency of the different Notch trans-membrane receptors [58].
While Notch-1 was found to be inhibitory for tumor growth,
Notch-2 was found to promote tumorgenesis in medulloblastoma
[59]. Comparing the rankings of Notch-1 and Notch-2 in our
study, we find that Notch-1 but not Notch-2 is strongly
overexpressed in oligodendrogliomas (rank 108 for Notch-1 vs.
2316 for Notch-2). This indicates that the characteristic overex-
pression of Notch-1 as part of the Notch pathway may contribute
to the better prognosis of oligodendrogliomas [53]. This is further
supported by the observation that Notch-1 is an important hub
gene in proneural oligodendrogliomas, which show improved
survival among different types of gliomas [60]. Indeed, except for
four oligodendrogliomas, we find that all our oligodendrogliomas
are classified as proneural utilizing subtype-specific gene expres-
sion classification signatures from [61]. Thus, our findings further
strengthen the important role of the Notch signaling pathway in
oligodendrogliomas. In addition to this, another important finding
is that the VEGF pathway is only affected in glioblastomas by the
overexpression of the VEGFA gene. This is in accordance with
generally observed histological characteristics of glioblastomas that
are highly angiogenic and characterized by the presence of
vascular proliferations [62].
Finally, we analyze the most discriminative pathways between
oligodendrogliomas, astrocytomas and glioblastomas shown in
Figure 5 at the level of single genes to investigate whether the
different types of gliomas utilize the same sets of genes to alter
pathway activities. Corresponding pathway-specific barplots and
Venn diagrams for the top 300 overexpressed genes are shown in
Figure 6. The Venn diagrams clearly indicate that the different
types of gliomas mainly utilize pathway-specific common core sets
of affected genes. These pathway-specific core gene sets are further
extended towards the type of glioma with the greatest number of
overexpressed genes. Since this observation might be of potential
relevance for the development of tumor-specific markers and
future treatment strategies, we have summarized the underlying
genes and their corresponding pathway memberships in the most
discriminative cancer signaling pathways in Table 2. Interestingly,
it is important to note that of the 41 listed genes 17 genes are
playing a role in at least two pathways and that 12 of these genes
are involved in three pathways. Among the genes involved in three
pathways, the combination of ECM-Receptor interaction, PI3K-
Akt signaling and Focal adhesion is strongly overrepresented,
Figure 6. Systematic characterization of the most discriminative signaling pathways distinguishing different types of gliomas. a)
Characteristic view on the most discriminative pathways between oligodendrogliomas, astrocytomas and glioblastomas at the level of the top 300
overexpressed genes in Figure 5. b) Selected gene-based view on the most discriminative signaling pathways shown in a). The Venn diagrams show
pathway-specific overlaps of overexpressed genes between the different types of gliomas. The strong overlap of genes between the different types
of gliomas indicates the presence of common core sets of affected genes. These pathway-specific core gene sets are further extended towards the
glioma with the greatest number of overexpressed genes. The corresponding genes are summarized in Table 2.
doi:10.1371/journal.pone.0100295.g006
ARHMM-Based Analysis of Tumor Expression Profiles
PLOS ONE | www.plosone.org 12 June 2014 | Volume 9 | Issue 6 | e100295
Table 2. Genes overexpressed in the most discriminative pathways distinguishing different types of gliomas.
Gene OD AS GBM Signaling Pathways Annotation
ANGPT2 0 0 1 PI3K-Akt Angiopoietin-2
CAV1 0 0 1 Focal Adh. Caveolin
COL1A1 0 0 1 ECM, Focal Adh., PI3K-Akt Collagen alpha-1(I) chain
COL4A2 0 0 1 ECM, Focal Adh., PI3K-Akt Canstatin
COL5A2 0 0 1 ECM, Focal Adh., PI3K-Akt Collagen alpha-2(V) chain
FN1 0 0 1 ECM, Focal Adh., PI3K-Akt Ugl-Y3
LAMB1 0 0 1 ECM, Focal Adh., PI3K-Akt Laminin subunit beta-1
LAMC1 0 0 1 ECM, Focal Adh., PI3K-Akt Laminin subunit gamma-1
VEGFA 0 0 1 Focal Adh., PI3K-Akt, VEGF Vascular endothelial growth factor A
RELA 0 1 0 PI3K-Akt Transcription factor p65
TGFB1 0 1 0 TGF-Beta Transforming growth factor beta-1
CDK2 0 1 1 PI3K-Akt Cyclin-dependent kinase 2
COL1A2 0 1 1 ECM, Focal Adh., PI3K-Akt Collagen alpha-2(I) chain
COL4A1 0 1 1 ECM, Focal Adh., PI3K-Akt Collagen alpha-1(IV) chain
LAMB2 0 1 1 ECM, Focal Adh., PI3K-Akt Laminin subunit gamma-1
TLR2 0 1 1 PI3K-Akt Toll-like receptor 2
BMP7 1 0 0 TGF-Beta Bone morphogenetic protein 7
NOG 1 0 0 TGF-Beta Noggin
NOTCH1 1 0 0 Notch Neurogenic locus notch homolog protein 1
PGF 1 0 0 Focal Adh., PI3K-Akt Placenta growth factor
RFC4 1 0 0 DNA Repair, Telomere Replication factor C subunit 4
RFC5 1 0 0 DNA Repair, Telomere Replication factor C subunit 5
RUVBL1 1 0 0 Telomere RuvB-like 1
BMP2 1 1 0 TGF-Beta Bone morphogenetic protein 2
CBLB 1 1 0 TGF-Beta E3 ubiquitin-protein ligase CBL-B
DDIT4 1 1 0 PI3K-Akt DNA damage-inducible transcript 4 protein
DLL3 1 1 0 Notch Delta-like protein 3
E2F5 1 1 0 TGF-Beta Transcription factor E2F5
ID1 1 1 0 TGF-Beta DNA-binding protein inhibitor ID-1
ID4 1 1 0 TGF-Beta DNA-binding protein inhibitor ID-4
MAML2 1 1 0 Notch Mastermind-like protein 2
CD44 1 1 1 ECM CD44 antigen
CDK4 1 1 1 PI3K-Akt Highly similar to Cell division protein kinase 4
COL3A1 1 1 1 ECM, Focal Adh., PI3K-Akt Collagen alpha-1(III) chain
DTX3L 1 1 1 Notch E3 ubiquitin-protein ligase DTX3L
EIF4EBP1 1 1 1 PI3K-Akt, TGF-Beta Euk. transl. initiation factor 4E-binding protein 1
F2R 1 1 1 PI3K-Akt Proteinase-activated receptor 1
ID3 1 1 1 TGF-Beta DNA-binding protein inhibitor ID-3
MYC 1 1 1 PI3K-Akt, TGF-Beta Myc proto-oncogene protein
TNC 1 1 1 ECM, Focal Adh., PI3K-Akt Tenascin
TP53 1 1 1 PI3K-Akt Cellular tumor antigen p53
Overexpressed genes representing the most discriminative cancer signaling pathways distinguishing oligodendrogliomas (OD), astrocytomas (AS) and glioblastomas
(GBM) at the level of the top 300 genes (Figure 6). Genes identified as overexpressed in a specific glioma type are indicated by ‘1’, otherwise ‘0’. The column ‘Signaling
Pathways’ represents the corresponding membership of each gene in one or more of these pathways.
doi:10.1371/journal.pone.0100295.t002
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which underlines the complexity and the interplay of pathway
alterations in tumors.
In summary, we successfully applied our autoregressive higher-
order HMM to the analysis of glioma gene expression profiles. We
were able to identify known important cancer signaling pathway
alterations, and we revealed systematic pathway-specific differ-
ences between different types of gliomas that may contribute to
improve the understanding of glioma development.
Conclusions
We have developed the novel model class of autoregressive
higher-order HMMs that utilize local chromosomal dependencies
of gene expression levels to improve the analysis of individual
tumor expression profiles. Autoregressive higher-order HMMs
form a very general model class that includes several well-known
standard models such as mixture models, autoregressive mixture
models, standard first-order HMMs, and standard higher-order
HMMs as special cases. Based on in-depth comparison studies on
breast cancer gene expression data, we have identified that
autoregressive higher-order HMMs robustly predict overexpressed
genes with known underlying increased copy numbers. These
results were also widely confirmed when we transferred trained
models to other similar but previously unseen breast cancer gene
expression profiles. We have further identified that autoregressive
HMMs are able to reach a solid characterization of differentially
expressed genes independent of the underlying copy number
status. Additional comparisons to closely related methods clearly
indicate that autoregressive higher-order HMMs are very useful
for the analysis of tumor expression profiles. This is also further
supported by the identification of known and previously unchar-
acterized hotspots of differential expression in glioblastomas (see
Appendix C in Text S1 for details).
Moreover, we were able to reveal novel interesting insights on
the alterations of expression levels in known cancer signaling
pathways across different types of gliomas by utilizing autore-
gressive higher-order HMMs. We identified characteristic path-
way-specific expression patterns distinguishing oligodendroglio-
mas, astrocytomas and glioblastomas. Gene-based views on these
pathways clearly indicate the presence of common core sets of
genes that are jointly altered in these gliomas and further extended
towards the specific type of glioma with the greatest number of
affected pathway-specific genes. Additionally, a large fraction of
these genes is involved in more than one pathway highlighting the
complexity and the interplay of affected signaling mechanisms
contributing to the development of gliomas. Our observations may
therefore have important implications for the development of
future treatment strategies.
Generally, the increase in performance reached by autoregres-
sive higher-order HMMs can be attributed to the more complex
modeling of local chromosomal dependencies between neighbor-
ing genes by utilizing a combination of higher-order state-
transitions and autoregressive emissions. The separate usage of
either (i) only higher-order state-transitions or (ii) only autore-
gressive emissions did not lead to performances reached by the
best-performing autoregressive HMMs that combine these two
features simultaneously. The best-performing models had state-
transitions of order two to three in combination with autore-
gressive emissions of order two to four. For the analysis of other
data sets, we suggest to consider the most parsimonious model of
the best-performing models. That is, one may use the HMM with
second-order state-transitions and second-order autoregressive
emissions. Since this only involves second-order state-transitions,
such a model can also be trained within reasonable time on large
data sets. Altogether, our results clearly indicate that autoregres-
sive higher-order HMMs are valuable tools for the analysis of
individual tumor expression profiles.
Currently, autoregressive higher-order HMMs enable to
analyze expression levels of genes in tumor with respect to their
linear chromosomal order. This linear processing of gene
expression levels allows to improve the predictions via the
modeling of existing local chromosomal dependencies. This
provides a solid basis that could be further extended by taking
prior knowledge about underlying transcriptional networks (e.g.
[63]) or spatial genome organization (e.g. [64]) into account.
Supporting Information
Text S1 Mathematical basics of the prior distributions
for initial state, state-transition and emission parame-
ters and details of the chosen prior hyperparameters are
given in the section ’Appendix A: Prior distributions’. A
detailed derivation of the Bayesian Baum-Welch algorithm for
autoregressive higher-order HMMs is given in the section
‘Appendix B: Bayesian Baum-Welch algorithm’. An in-depth
analysis of identified hotspots of differential expression in gliomas
is given in the section ‘Appendix C: Application of Autoregressive
Higher-Order Hidden Markov Models to glioma data’. The
supporting Figures S1–S8 are provided in the section ‘Supporting
Figures’. The supporting Tables S1–S4 are given in the section
‘Supporting Tables’.
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